All type of patients: 2 trials - METEOR - CABOSUN
| cabozantinib vs everolimus | No demonstrated result suggested death (overall survival) by 33% (not demonstrated) suggested progression or death (progression free survival PFS) by 42% (not demonstrated) | |
| cabozantinib vs sunitinib | No demonstrated result suggested progression or death (progression free survival PFS) by 34% (not demonstrated) |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
